Can Respiratory Rate Predict the Risk of Deterioration of Septic Patients
The primary objective is to determine if the trend in Respiratory Rate measurements provided by the device under investigation can be used to predict an increase in Sequential/Sepsis-related Organ Failure Assessment (SOFA) score.
The RR trend will be measured as the difference between the RR recorded by the device at a point 15 minutes after commencement of treatment, as per the standard of care for patients suspected of being septic, and a point 3 hours following this.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
The primary objective is to determine if the trend in Respiratory Rate measurements provided by the device under investigation can be used to predict an increase in Sequential/Sepsis-related Organ Failure Assessment (SOFA) score.
The RR trend will be measured as the difference between the RR recorded by the device at a point 15 minutes after commencement of treatment, as per the standard of care for patients suspected of being septic, and a point 3 hours following this.
Secondary objective The secondary objective is to test if Respiratory Rate can help identify patients at increased risk of 30 day mortality.
The null Hypotheses of the planned comparison is that there is no difference in the RR trend in the 3 hours following commencement of treatment for sepsis in subjects who have an increase in SOFA score by 2 or more points and those who have a change in SOFA score of +1 or less.
The change in SOFA score will be measured at point of commencement of treatment and at 6 hours following commencement of treatment, or nearest available SOFA score determination.
Respiratory Rate captured during admission could have a predictive course for cohort of interest
The time points for reviewing the RR will be as follows:
(i) The last measurement (ii) The trend over 3 hours following commencement of treatment as per the standard of care for patients suspected of being septic.
(iii) The trend over the entire duration of admission
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
South West Jutland
-
Esbjerg, South West Jutland, Danimarca, DK-6700
- Hospital of South West Jutland, Department of Emergency Medicine
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion criteria
- ≥ 18 Years
- Admitted for a minimum of 12 hours
- Have been diagnosed with sepsis
Sepsis diagnosis confirmed by documented or suspected infection (ordering of blood culture or other microbiological investigation by the clinician) and ≥1 of the following presenting within the first 4 hours of admission:
- Fever or hypothermia, Core temperature > 38.3 or < 36 °C
- Heart rate > 90/min
- Respiratory rate > 20/min
- Altered consciousness/mental state, defined as GCS < 15
- Hyperglycemia, (BS > 6.7 mmol/L non-diabetic)
- LKC > 12 *10^9 or < 4*10^9,
- Normal LKC with > 10 % immature cells,
- CRP > highest normal local lab. Interval
- Hypotension: Systolic BP <90 mmHg, or drop in systolic BP > 40
- Hypoxemia: PaO2 < 8.5 Kpa or PaO2/FiO2 < 40 or tissue perfusion: P-lactate > 1.6
- Creatinine . 177 µmol/L
- Acute oliguria (Diuresis per hour ,0.5 ml/kg/t or 45 ml/t in 2 hours)
- Coagulopathy: Spontaneous INR > 1.5, or apt > 60 sec, thrombocytopenia
- Paralytic ileus (absence of bowel sounds)
- Hyperbilirubinemia > 34µmol/L
- Are willing to voluntarily sign a statement of informed consent to participate in this investigation
Exclusion criteria
- Allergic to medical grade skin adhesive
- Pregnant women during second and third trimester
- Continuous long term steroid use. Defined as not using steroids in the 4 weeks previous to enrolment
- Patients under the influence of substance abuse (drug or alcohol) that may interfere with their ability to cooperate and comply with the investigation procedures
- Any disorder, including cognitive dysfunction, which would affect the ability to accurately complete questionnaires and freely give full informed consent. This will be determined by the Abbreviated Mental Test Score (AMT) Cannot be followed a second time if admitted again at a later date during the study period
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
|---|
|
Suspicion of Sepsis
Patients who are admitted and are diagnosed with sepsis will be recruited for this investigation.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
RespiraSense triggered escalation in SOFA score
Lasso di tempo: 15 minutes after commencement of treatment, as per the standard of care for patients suspected of being septic, and a point 3 hours following this.
|
Escalation of SOFA score by 2 or more points.
The primary endpoint will be evaluated with an ANCOVA with escalation of SOFA score by 2 or more points as a factor and mean RR in the first hour of treatment as a covariate.
|
15 minutes after commencement of treatment, as per the standard of care for patients suspected of being septic, and a point 3 hours following this.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Upward trend in Respiratory Rate as a predictor of 30 day mortality
Lasso di tempo: 30 days after discharge
|
The secondary endpoint is the 30 day mortality rate after discharge.
|
30 days after discharge
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Upward trend in Respiratory Rate as a predictor of 30 day readmission.
Lasso di tempo: 30 days after discharge
|
The secondary endpoint is the 30 day readmission rate after discharge.
|
30 days after discharge
|
Collaboratori e investigatori
Sponsor
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- PMD-CS-006ii
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .